27920636|t|Identifying CNVs in 15q11q13 and 16p11.2 of Patients with Seizures Increases the Rates of Detecting Pathogenic Changes
27920636|a|Chromosomal changes are frequently observed in patients with syndromic seizures. Understanding the genetic etiology of this pathology is crucial for the guidance and genetic counseling of families as well as for the establishment of appropriate treatment. A combination of MLPA kits was used to identify pathogenic CNVs in a group of 70 syndromic patients with seizures. Initially, a screening was performed for subtelomeric changes (MLPA P036 and P070 kits) and for the regions most frequently related to microdeletion / microduplication syndromes (MLPA P064). Subsequently, the MLPA P343 was used to identify alterations in the 15q11q13, 16p11.2, and 22q13 regions. Screening with MLPA P343 allowed a 10-15.7% increase in the detection rate of CNVs reinforcing the importance of investigating changes in 15q11q13 and 16p11.2 in syndromic patients with seizures. We also demonstrated that the MLPA technique is an alternative with a great diagnostic potential, and we proposed its use as part of the initial assessment of syndromic patients with seizures.
27920636	12	16	CNVs	T039	C0009850
27920636	20	28	15q11q13	T026	C1953345
27920636	33	40	16p11.2	T026	C1520678
27920636	44	52	Patients	T101	C0030705
27920636	58	66	Seizures	T184	C0036572
27920636	67	76	Increases	T169	C0442805
27920636	81	86	Rates	T081	C1521828
27920636	90	99	Detecting	T061	C1511790
27920636	100	110	Pathogenic	T169	C0543483
27920636	111	118	Changes	T169	C0392747
27920636	119	138	Chromosomal changes	UnknownType	C0544871
27920636	166	174	patients	T101	C0030705
27920636	180	198	syndromic seizures	T184	C0036572
27920636	218	234	genetic etiology	T169	C1314792
27920636	243	252	pathology	T046	C0677042
27920636	272	280	guidance	T201	C3854153
27920636	285	303	genetic counseling	T061	C0017382
27920636	307	315	families	T099	C0015576
27920636	335	348	establishment	T061	C0511063
27920636	352	373	appropriate treatment	T201	C3640049
27920636	377	388	combination	T080	C0205195
27920636	392	401	MLPA kits	T063	C3494189
27920636	423	433	pathogenic	T169	C0543483
27920636	434	438	CNVs	T039	C0009850
27920636	444	449	group	UnknownType	C0681860
27920636	456	474	syndromic patients	T101	C0030705
27920636	480	488	seizures	T184	C0036572
27920636	503	512	screening	T058	C0220908
27920636	531	543	subtelomeric	T026	C1953345
27920636	544	551	changes	T169	C0392747
27920636	553	562	MLPA P036	T063	C3494189
27920636	567	576	P070 kits	T063	C3494189
27920636	590	597	regions	T026	C1953345
27920636	625	638	microdeletion	T047	C1954751
27920636	641	667	microduplication syndromes	T047	C0039082
27920636	669	678	MLPA P064	T063	C3494189
27920636	699	708	MLPA P343	T063	C3494189
27920636	730	741	alterations	UnknownType	C0544871
27920636	749	757	15q11q13	T026	C1953345
27920636	759	766	16p11.2	T026	C1520678
27920636	772	785	22q13 regions	T026	C1521113
27920636	787	796	Screening	T058	C0220908
27920636	802	811	MLPA P343	T063	C3494189
27920636	831	839	increase	T169	C0442805
27920636	847	856	detection	T061	C1511790
27920636	857	861	rate	T081	C1521828
27920636	865	869	CNVs	T039	C0009850
27920636	900	913	investigating	T169	C1292732
27920636	914	921	changes	UnknownType	C0544871
27920636	925	933	15q11q13	T026	C1953345
27920636	938	945	16p11.2	T026	C1520678
27920636	949	967	syndromic patients	T101	C0030705
27920636	973	981	seizures	T184	C0036572
27920636	1013	1027	MLPA technique	T063	C3494189
27920636	1034	1045	alternative	T077	C1523987
27920636	1059	1069	diagnostic	T169	C0348026
27920636	1070	1079	potential	T080	C3245505
27920636	1120	1138	initial assessment	T033	C0150637
27920636	1142	1160	syndromic patients	T101	C0030705
27920636	1166	1174	seizures	T184	C0036572